Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN.
作者信息
Mossel Eric C, Sainz Bruno, Garry Robert F, Peters C J
机构信息
Colorado State University, Fort Collins 80523, USA.
出版信息
Adv Exp Med Biol. 2006;581:503-6. doi: 10.1007/978-0-387-33012-9_89.
Abstract
摘要
相似文献
1
Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN.
Adv Exp Med Biol. 2006;581:503-6. doi: 10.1007/978-0-387-33012-9_89.
2
The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Intervirology. 2007;50(2):156-60. doi: 10.1159/000098242. Epub 2006 Dec 22.
3
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Antivir Ther. 2004 Dec;9(6):1003-11.
4
Interferon-beta 1a and SARS coronavirus replication.
Emerg Infect Dis. 2004 Feb;10(2):317-9. doi: 10.3201/eid1002.030482.
5
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
6
In vitro inhibition of SARS virus replication by human interferons.
Scand J Infect Dis. 2004;36(11-12):829-31. doi: 10.1080/00365540410021144.
7
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
8
Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain.
J Virol. 2007 Nov;81(21):11620-33. doi: 10.1128/JVI.00702-07. Epub 2007 Aug 22.
9
Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Chemotherapy. 2008;54(3):176-80. doi: 10.1159/000140361. Epub 2008 Jun 18.
10
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.
Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8. doi: 10.1016/j.bbrc.2004.11.128.
引用本文的文献
1
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.
Int J Mol Sci. 2022 Apr 20;23(9):4545. doi: 10.3390/ijms23094545.
2
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Front Immunol. 2021 Oct 1;12:752227. doi: 10.3389/fimmu.2021.752227. eCollection 2021.
3
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00299-20. Print 2021 Jun 16.
4
Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID‑19 (Review).
Int J Mol Med. 2021 Mar;47(3). doi: 10.3892/ijmm.2021.4844. Epub 2021 Jan 15.
5
Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses.
JAKSTAT. 2016 May 18;5(1):e1173804. doi: 10.1080/21623996.2016.1173804. eCollection 2016.
6
Antiviral activity of Rheum palmatum methanol extract and chrysophanol against Japanese encephalitis virus.
Arch Pharm Res. 2014;37(9):1117-23. doi: 10.1007/s12272-013-0325-x. Epub 2014 Jan 7.
7
Tumor necrosis factor and interferon: cytokines in harmony.
Curr Opin Microbiol. 2008 Aug;11(4):378-83. doi: 10.1016/j.mib.2008.05.015. Epub 2008 Jul 1.
8
Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus.
J Virol. 2007 Nov;81(21):12049-60. doi: 10.1128/JVI.00969-07. Epub 2007 Aug 29.
本文引用的文献
1
Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma.
Virol J. 2005 Feb 23;2:14. doi: 10.1186/1743-422X-2-14.
2
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Antivir Ther. 2004 Dec;9(6):1003-11.
3
Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus.
J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005.
4
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
5
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
J Clin Virol. 2004 Jul;30(3):211-3. doi: 10.1016/j.jcv.2003.11.013.
6
Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
J Infect Dis. 2004 Apr 1;189(7):1164-7. doi: 10.1086/382597. Epub 2004 Mar 12.
7
Interferon-beta 1a and SARS coronavirus replication.
Emerg Infect Dis. 2004 Feb;10(2):317-9. doi: 10.3201/eid1002.030482.
8
Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.
J Virol. 2004 Mar;78(6):3162-9. doi: 10.1128/jvi.78.6.3162-3169.2004.
9
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Nat Med. 2004 Mar;10(3):290-3. doi: 10.1038/nm1001. Epub 2004 Feb 22.
10
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study.
JAMA. 2003 Dec 24;290(24):3222-8. doi: 10.1001/jama.290.24.3222.
Zotero 插件